AstraZeneca vaccine effective in U.S., no higher risk of blood clots

Economy Society

Britain's AstraZeneca PLC said Monday its coronavirus vaccine was 79 percent effective in preventing the disease caused by the novel coronavirus in a clinical trial conducted in the United States and two South American countries. It also said experts have identified no safety concerns related to the vaccine, including any increased risk of blood clots. Blood clots among those who received the shots have been reported in Europe, leading France and other countries to temporarily suspend use of the AstraZeneca vaccine. The biopharmaceutical company said it is preparing to seek emergency use autho...

Kyodo News

Kyodo News Society